Compulsive scratching
Also known as: Excoriation - neurotic
Methodology & AI Transparency ⓘ
Compulsive scratching Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry L98.1: Compulsive scratching is managed within Skin & Dermatology (aka Excoriation - neurotic).
- 3 Typical cash cost range: Primary evaluation for Compulsive scratching incorporates contact/systemic trigger review [Compulsive scratching L98.1] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Compulsive scratching: Affected Body Surface in Compulsive scratching (L98.1: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L98.1)) and Fasting Lipids & in Compulsive scratching (L98.1: ALT (if systemic).
Ask our AI Specialists anything about Compulsive scratching
What Is Compulsive scratching?
Recognized across U.S. clinical coding as L98.1 (Skin & Dermatology), Compulsive scratching (also termed Excoriation - neurotic) is evaluated via contact/systemic trigger review [Compulsive scratching L98.1] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in skin & dermatology, Compulsive scratching (L98.1) involves cutaneous immune skewing in Compulsive scratching (L98.1: (Th2/IL-4/IL-13 in atopic). progression correlates with shifts in Affected Body Surface in Compulsive scratching (L98.1: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L98.1)).
Common Symptoms & Clinical Signs
- • Presentation of Compulsive scratching (L98.1): compromised epidermal barrier in Compulsive scratching (L98.1: with dryness, fissuring,)
- • Secondary Compulsive scratching clinical sign: post-inflammatory hyperpigmentation, facial in Compulsive scratching (L98.1: flushing, or pitted)
- • Symptom flares in Compulsive scratching correlating with Affected Body Surface in Compulsive scratching (L98.1: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L98.1)
- • Functional skin & dermatology impact requiring contact/systemic trigger review [Compulsive scratching L98.1] evaluation (L98.1)
Compulsive scratching Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L98.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Compulsive scratching (L98.1: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L98.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Compulsive scratching (L98.1: ALT (if systemic) | Within baseline reference limits (L98.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Compulsive scratching (L98.1: & hs-CRP) | 25(OH)D 40–65 ng/mL (L98.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Compulsive scratching
Treatment selection for Compulsive scratching depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Compulsive scratching)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Baricitinib in combination with skin-applied steroids on eczema symptoms, quality: What a 329-Participant Study Found Baricitinib plus TCS vs. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-07-15 • Phase III Randomized Trial | N = 329 | 93/100 | PMID 33834521 ↗ |
| New Insights on Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate: What a 741-Participant Study Found Lesion count reductions were significantly greater with CAB versus its dyads and vehicle gel as early as week 4, with substantial reductions observed after 12 weeks of treatment. Journal of drugs in dermatology : JDD • 2024-03-01 • Phase III Randomized Trial | N = 741 | 93/100 | PMID 38443130 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of dupilumab in patients with severe chronic hand eczema with Dupilumab was efficacious and well tolerated. The British journal of dermatology • 2023-09-15 • Randomized Controlled Trial | N = 20 | 88/100 | PMID 37170922 ↗ |
| Can This Approach Help? Inside the Latest Research on Acitretin versus etretinate in severe psoriasis. A gold-standard blind randomized The differences found between acitretin and etretinate may be related to higher maximum plasma concentrations of acitretin. Acta dermato-venereologica. Supplementum • 1989-01-15 • Randomized Controlled Trial | N = 127 | 88/100 | PMID 2532847 ↗ |
| Can This Approach Help? Inside the Latest Research on Regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in These exploratory clinical improvements are accompanied by sustained increases in CD25 bright Tregs. Nature communications • 2024-10-25 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 39455575 ↗ |
Compulsive scratching Patient Community & “People Like Me” Threads
Filter Compulsive scratching community threads and patient logs by age, biological sex, dosage, and treatment duration.